| Category | Small molecules |
|---|---|
| Form/Appearance | White powder |
| Catalog Number | orb61092 |
| Formula | C51H79NO13 |
| Purity | > 99% pure |
| Chemical Name | (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S, 26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26, 27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3- [(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]- 1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26- hexamethyl-23, |
| Conjugation | Unconjugated |
| CAS Number | [53123-88-9] |
| MW | 914.18 g/mol |
| PubChem CID | CID 5284616 |
| Application notes | In vitro: Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of -0.1 nM, more potently than iRap and AP21967 with IC50 of -5 nM and -10 nM, respectively.In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control.Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of > 25 μM despite the similar extent of the inhibition of mTOR signaling.Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR.In vivo: Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size.Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors.Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling.Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. |
| Note | For research use only. |
| Target | Rapamycin. Clinical trials of Rapamycin |
| DMSO | 21 mM |
| Storage | Store at or below -20°C. |
| Expiration Date | 12 months from date of receipt. |
| Description | Rapamycin (Sirolimus, AY-22989, WY-090217) is a specific mTOR inhibitor with IC50 of -0.1 nM. A Phase II study of Rapamycin to erase angiofibromas in patients with Tuberous Sclerosis Complex (TSC) is currently ongoing. |
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control.
Rapamycin (Sirolimus) Chemical Structure
Molecular Weight: 914.18
Molecular Weight: 914.18
Chemical structure of rapamycin
- 5 imagesRaptor antibody [orb6836]
ELISA, IF, IHC-Fr, IHC-P, WB
Bovine, Canine, Equine, Gallus, Human, Mouse, Rabbit, Rat
Rabbit
Polyclonal
Unconjugated
100 μl, 200 μl, 50 μl -
- 5 images
-
- 3 imagesmTOR (Phospho-S2448) antibody [orb315804]
ICC, IF, IHC-P, IP, WB
Human, Mouse, Rat, Sheep
Rabbit
Polyclonal
30 μl, 100 μl, 200 μl -
- 2 imagesmTOR antibody [orb13590]
ELISA, FC, ICC, IF, IHC-Fr, IHC-P, WB
Bovine, Canine, Equine, Gallus, Goat, Human, Mouse, Rabbit, Rat, Sheep
Rabbit
Polyclonal
Unconjugated
100 μl, 200 μl, 50 μl -
- 3 images
-
